busulfan has been researched along with Hepatic Veno Occlusive Disease in 128 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Plasma concentrations of oral busulfan (BU) were measured in multiple myeloma (MM) patients undergoing autologous peripheral blood stem cell transplantation (ASCT) with a double alkylating conditioning protocol in order to individualise doses of BU based on individual pharmacokinetic parameters and to reduce toxicities related to BU exposure." | 9.12 | Absence of veno-occlussive disease in a cohort of multiple myeloma patients undergoing autologous stem cell transplantation with targeted busulfan dosage. ( Broto, A; Brunet, S; Clopés, A; Farré, R; Mangues, MA; Martino, R; Moreno, E; Queraltó, JM; Sierra, J; Sureda, A, 2006) |
| "Between October 1988 and December 1992, 167 patients with leukemia receiving marrow transplants from HLA-identical donors and conditioned with cyclophosphamide (120 mg/kg) were randomized to additional treatment with either busulfan (16 mg/kg, n = 88) or total body irradiation (TBI; n = 79)." | 9.07 | A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. ( Lenhoff, S; Ljungman, P; Nikoskelainen, J; Parkkali, T; Remberger, M; Ringdén, O; Ruutu, T; Sallerfors, B; Vindeløv, L; Volin, L, 1994) |
| "The use of cyclosporine-A/methotrexate (CyA/MTX) for graft-versus-host disease (GVHD) prophylaxis is safe and effective for patients undergoing allogeneic bone marrow transplantation after preparation with cyclophosphamide and total body irradiation." | 9.07 | Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide. ( Essell, JH; Halvorson, RD; Harman, GS; Johnson, RA; Rubinsak, JR; Snyder, MJ; Thompson, JM, 1992) |
| " We assessed the incidence of and risk for hepatic veno-occlusive disease (VOD) for neuroblastoma patients who underwent autologous SCT with busulfan and melphalan (BuMel) at eight centers following Children's Oncology Group (COG)-based induction chemotherapy." | 7.96 | Veno-occlusive disease after high-dose busulfan-melphalan in neuroblastoma. ( Desai, AV; Dupuis, LL; Dvorak, CC; Essa, M; Frangoul, H; Grupp, S; Irwin, MS; Jacobsohn, D; Kletzel, M; Lin, TF; Perez-Albuerne, E; Ranalli, M; Schechter, T; Seif, AE; Soni, S; Yanik, G, 2020) |
| "This mono-institutional observational study was conducted to determine incidence, severity, risk factors, and outcome of sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) in high-risk Ewing sarcoma (ES) patients treated with intravenous busulfan and melphalan (BU-MEL) followed by autologous stem cell transplantation (ASCT)." | 7.88 | Sinusoidal obstruction syndrome/veno-occlusive disease after high-dose intravenous busulfan/melphalan conditioning therapy in high-risk Ewing Sarcoma. ( Abate, ME; Cammelli, S; Carretta, E; Cesari, M; Ferrari, S; Longhi, A; Paioli, A; Palmerini, E; Picci, P; Piscaglia, F, 2018) |
| "Objective The objective of this study was to compare clinical outcomes in children undergoing hematopoietic cell transplantation who received levetiracetam versus those who received phenytoin for the prevention of busulfan-induced seizures." | 7.85 | Levetiracetam for the prevention of busulfan-induced seizures in pediatric hematopoietic cell transplantation recipients. ( Floeter, AE; McCune, JS, 2017) |
| "At our Institute, during the last decade, the incidence of hepatic veno-occlusive disease (HVOD) appears to be on the increase among pediatric patients treated with BU-thiotepa (BU-TTP)-conditioning regimen." | 7.74 | Risk factors for hepatic veno-occlusive disease: a retrospective unicentric study in 116 children autografted after a high-dose BU-thiotepa regimen. ( Amoroso, L; Benhamou, E; Cacchione, A; Couanet, DV; Hartmann, O; LeMaitre, A; Simonnard, N, 2008) |
| "We investigated the occurrence of hepatic veno-occlusive disease (VOD) after allogeneic bone marrow transplantation (BMT) in 241 adults conditioned with busulfan + cyclophosphamide at a single institute and retrospectively compared 186 patients who received oral busulfan (O-Bu group) with 55 patients who received intravenous busulfan (I-Bu group)." | 7.73 | Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation. ( Chi, HS; Choi, SJ; Kim, SE; Kim, WK; Lee, JH; Lee, JS; Lee, KH; Lee, MS; Park, CJ, 2005) |
| "We investigated whether adjusting the oral busulfan (BU) dosage on the basis of early pharmacokinetic data to achieve a targeted drug exposure could reduce transplant-related complications in children with advanced hematologic malignancies." | 7.70 | Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies. ( Chan, KW; Choroszy, M; Danielson, M; Felix, EA; Madden, T; Petropoulos, D; Przepiorka, D; Sprigg-Saenz, HA; Tran, HT; Worth, LL, 2000) |
| "Hepatic veno-occlusive disease (HVOD) is a frequent life-threatening toxicity in patients undergoing bone marrow transplantation (BMT) after the administration of a high-dose busulfan-containing regimen." | 7.69 | Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation. ( Boland, I; Challine, D; Deroussent, A; Gouyette, A; Hartmann, O; Koscielny, S; Lemerle, J; Valteau-Couanet, D; Vassal, G, 1996) |
| "Risk factors for hepatic veno-occlusive disease (HVOD) were analysed in a population of 136 autografted children who received high-dose busulfan (BU) as part of a conditioning regimen." | 7.68 | Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children. ( Benhamou, E; Brugieres, L; Hartmann, O; Lemerle, J; Méresse, V; Valteau-Couanet, D; Vassal, G, 1992) |
| "We performed a retrospective analysis of the incidence, risk factors, and clinical outcome of hepatic veno-occlusive disease (VOD) in 50 children prepared for bone marrow transplantation with busulfan (16 mg/kg) and cyclophosphamide (200 mg/kg)." | 7.68 | Hepatic veno-occlusive disease post-bone marrow transplantation in children conditioned with busulfan and cyclophosphamide: incidence, risk factors, and clinical outcome. ( Kohn, D; Lenarsky, C; Ozkaynak, MF; Parkman, R; Sender, L; Weinberg, K, 1991) |
| "Busulfan-treated patients had an increased risk of veno-occlusive disease (VOD) of the liver (12% v 1%, P =." | 6.69 | Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplanta ( Jacobsen, N; Lenhoff, S; Ljungman, P; Mellander, L; Nikoskelainen, J; Parkkali, T; Remberger, M; Ringdén, O; Ruutu, T; Sallerfors, B; Vindeløv, L; Volin, L, 1999) |
| " Getting more insight into the association between busulfan exposure and the development of VOD/SOS enables further optimization of dosing and treatment strategies." | 5.72 | Association Between the Magnitude of Intravenous Busulfan Exposure and Development of Hepatic Veno-Occlusive Disease in Children and Young Adults Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation. ( Ansari, M; Bartelink, IH; Bittencourt, H; Boelens, JJ; Bognàr, T; Bredius, RGM; Chiesa, R; Cowan, MJ; Cuvelier, GDE; Dvorak, C; Egberts, TCG; Güngör, T; Hassan, M; Hempel, G; Kletzel, M; Krajinovic, M; Lalmohamed, A; Long-Boyle, JR; Lund, T; Marktel, S; Nath, CE; Orchard, PJ; Rademaker, CMA; Savic, RM; Shaw, PJ; Slatter, MA; Théoret, Y; Versluys, AB; Wynn, RF, 2022) |
| "Of those, 47% were transplanted for hematological malignancies and 53% for inherited hemoglobinopathies." | 5.56 | Busulfan clearance does not predict the development of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation. ( Al-Huneini, M; Al-Khabori, M; Al-Rawas, A; Al-Za'abi, M; Dennison, D; Salman, B, 2020) |
| "We retrospectively analyzed 132 malignant lymphoma patients who underwent ASCT." | 5.43 | High pre-transplant serum ferritin and busulfan-thiotepa conditioning regimen as risk factors for hepatic sinusoidal obstructive syndrome after autologous stem cell transplantation in patients with malignant lymphoma. ( Cheong, JW; Hwang, DY; Jang, JE; Kim, JS; Kim, SJ; Kim, Y; Lee, JY; Min, YH; Yang, WI, 2016) |
| "Busulfan is a commonly used chemotherapeutic agent in myeloablative conditioning regimens for allogeneic hematopoietic cell transplantation (allo-HCT)." | 5.42 | Subacute hepatic necrosis mimicking veno-occlusive disease in a patient with HFE H63D homozygosity after allogeneic hematopoietic cell transplantation with busulfan conditioning. ( Boyer, MW; Chen, S; Chen, X; Hildebrandt, GC; McDonald, GB; Osborn, JD, 2015) |
| "To evaluate long-term survival of the first cohort of stage-4 neuroblastoma patients treated with the N7 induction chemotherapy, surgery of the primary tumor and high-dose chemotherapy (HDC) containing Busulfan-Melphalan (Bu-Mel) followed by autologous stem cell transplantation (ASCT)." | 5.19 | Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy. ( Bergeron, C; Bouzy, J; Chastagner, P; Coze, C; Ducassou, S; Hartmann, O; Le Deley, MC; Le Teuff, G; Michon, J; Plantaz, D; Rubie, H; Sirvent, N; Valteau-Couanet, D, 2014) |
| "Plasma concentrations of oral busulfan (BU) were measured in multiple myeloma (MM) patients undergoing autologous peripheral blood stem cell transplantation (ASCT) with a double alkylating conditioning protocol in order to individualise doses of BU based on individual pharmacokinetic parameters and to reduce toxicities related to BU exposure." | 5.12 | Absence of veno-occlussive disease in a cohort of multiple myeloma patients undergoing autologous stem cell transplantation with targeted busulfan dosage. ( Broto, A; Brunet, S; Clopés, A; Farré, R; Mangues, MA; Martino, R; Moreno, E; Queraltó, JM; Sierra, J; Sureda, A, 2006) |
| "A strong relationship has been demonstrated between high systemic exposure to busulfan and the occurrence of hepatic veno-occlusive disease (HVOD) after a busulfan-cyclophosphamide regimen (BU CY)." | 5.10 | In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa). ( Boland, I; Bouligand, J; Deroussent, A; Hartmann, O; Kalifa, C; Valteau-Couanet, D; Vassal, G, 2003) |
| "Thirty-six adults with chronic myelogenous leukemia (CML) in second or greater chronic phase, accelerated phase, or blast crisis underwent marrow or blood stem cell transplantation from an HLA-matched sibling using high-dose thiotepa, busulfan and cyclophosphamide (TBC) as the preparative regimen." | 5.09 | Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia. ( Andersson, B; Champlin, R; Deisseroth, AB; Gajewski, J; Giralt, S; Ippoliti, C; Khouri, I; Körbling, M; Lee, MS; Mehra, R; Przepiorka, D; Thall, P; van Besien, K, 1999) |
| "67 consecutive patients undergoing transplantation with allogeneic bone marrow (donated by a relative) in whom busulfan plus cyclophosphamide was used as the preparative regimen and cyclosporine plus methotrexate was used to prevent graft-versus-host disease." | 5.08 | Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial. ( Allerton, JP; Callander, N; Essell, JH; Halvorson, R; Harman, GS; Lew, V; Lewis, SK; Schroeder, MT; Snyder, M; Thompson, JM, 1998) |
| "The use of cyclosporine-A/methotrexate (CyA/MTX) for graft-versus-host disease (GVHD) prophylaxis is safe and effective for patients undergoing allogeneic bone marrow transplantation after preparation with cyclophosphamide and total body irradiation." | 5.07 | Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide. ( Essell, JH; Halvorson, RD; Harman, GS; Johnson, RA; Rubinsak, JR; Snyder, MJ; Thompson, JM, 1992) |
| "Between October 1988 and December 1992, 167 patients with leukemia receiving marrow transplants from HLA-identical donors and conditioned with cyclophosphamide (120 mg/kg) were randomized to additional treatment with either busulfan (16 mg/kg, n = 88) or total body irradiation (TBI; n = 79)." | 5.07 | A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. ( Lenhoff, S; Ljungman, P; Nikoskelainen, J; Parkkali, T; Remberger, M; Ringdén, O; Ruutu, T; Sallerfors, B; Vindeløv, L; Volin, L, 1994) |
| " We assessed the incidence of and risk for hepatic veno-occlusive disease (VOD) for neuroblastoma patients who underwent autologous SCT with busulfan and melphalan (BuMel) at eight centers following Children's Oncology Group (COG)-based induction chemotherapy." | 3.96 | Veno-occlusive disease after high-dose busulfan-melphalan in neuroblastoma. ( Desai, AV; Dupuis, LL; Dvorak, CC; Essa, M; Frangoul, H; Grupp, S; Irwin, MS; Jacobsohn, D; Kletzel, M; Lin, TF; Perez-Albuerne, E; Ranalli, M; Schechter, T; Seif, AE; Soni, S; Yanik, G, 2020) |
| "This mono-institutional observational study was conducted to determine incidence, severity, risk factors, and outcome of sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) in high-risk Ewing sarcoma (ES) patients treated with intravenous busulfan and melphalan (BU-MEL) followed by autologous stem cell transplantation (ASCT)." | 3.88 | Sinusoidal obstruction syndrome/veno-occlusive disease after high-dose intravenous busulfan/melphalan conditioning therapy in high-risk Ewing Sarcoma. ( Abate, ME; Cammelli, S; Carretta, E; Cesari, M; Ferrari, S; Longhi, A; Paioli, A; Palmerini, E; Picci, P; Piscaglia, F, 2018) |
| "Objective The objective of this study was to compare clinical outcomes in children undergoing hematopoietic cell transplantation who received levetiracetam versus those who received phenytoin for the prevention of busulfan-induced seizures." | 3.85 | Levetiracetam for the prevention of busulfan-induced seizures in pediatric hematopoietic cell transplantation recipients. ( Floeter, AE; McCune, JS, 2017) |
| "Pre-conditioning regimens before hematopoietic stem cell transplantation (HSCT), such as total body irradiation (TBI) or busulfan/cyclophosphamide (BU/CY), are associated with hepatic veno-occlusive disease (HVOD)." | 3.81 | Evaluation of the effects of preconditioning regimens on hepatic veno-occlusive disease in mice after hematopoietic stem cell transplantation. ( Chen, C; Fang, T; Fu, J; Huang, Y; Mi, H; Qiao, J; Xu, K; Yang, N; Zeng, L, 2015) |
| "Total body irradiation, Busulfan and Cyclophosphamide all led to the damage of liver vascular endothelium in hematopoietic stem cell transplantation, and may be the important triggers of hepatic veno-occlusive disease." | 3.76 | [Effects of pretreatment regimen on mice liver injury in hematopoietic stem cell transplantation]. ( Jia, L; Xu, KL; Xu, SJ; Yan, ZL; Zeng, LY, 2010) |
| "At our Institute, during the last decade, the incidence of hepatic veno-occlusive disease (HVOD) appears to be on the increase among pediatric patients treated with BU-thiotepa (BU-TTP)-conditioning regimen." | 3.74 | Risk factors for hepatic veno-occlusive disease: a retrospective unicentric study in 116 children autografted after a high-dose BU-thiotepa regimen. ( Amoroso, L; Benhamou, E; Cacchione, A; Couanet, DV; Hartmann, O; LeMaitre, A; Simonnard, N, 2008) |
| "To explore the safety and efficacy of low dose heparin for the prevention of hepatic veno-occlusive disease (VOD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) conditioned with busulfan and cyclophosphamide (BU-CY2) and the ideal time frame of the heparin administration." | 3.74 | [Low dose heparin for the prevention of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation]. ( Chen, J; Chen, ST; Zeng, HL; Zhang, T; Zhong, J; Zhu, KE, 2007) |
| "We investigated the occurrence of hepatic veno-occlusive disease (VOD) after allogeneic bone marrow transplantation (BMT) in 241 adults conditioned with busulfan + cyclophosphamide at a single institute and retrospectively compared 186 patients who received oral busulfan (O-Bu group) with 55 patients who received intravenous busulfan (I-Bu group)." | 3.73 | Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation. ( Chi, HS; Choi, SJ; Kim, SE; Kim, WK; Lee, JH; Lee, JS; Lee, KH; Lee, MS; Park, CJ, 2005) |
| "75-17 years), treated with high-dose chemotherapy containing busulfan followed by hematopoietic stem cell transplantation for neuroblastoma (n=112) or brain tumor (n=74) between 1988 and 1998, were investigated." | 3.73 | Platelet transfusion containing ABO-incompatible plasma and hepatic veno-occlusive disease after hematopoietic transplantation in young children. ( Aupérin, A; Benhamou, E; Hartmann, O; Lapierre, V; Mahé, C; Oubouzar, N; Stambouli, F; Tiberghien, P; Tramalloni, D, 2005) |
| " Graft-versus-host disease prophylaxis consisted of cyclosporine and a short course of methotrexate." | 3.71 | A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome. ( Kabisch, H; Kröger, N; Krüger, W; Renges, H; Schetelig, J; Schrum, J; Siegert, W; Stute, N; Zabelina, T; Zander, AR, 2001) |
| " Graft-versus-host disease (GVHD) prophylaxis was attempted with cyclosporine A (CYA) and methotrexate." | 3.70 | [Severe hepatic veno-occlusive disease (VOD) which was successfully treated with supportive therapy, but subsequently developed late-recurrence]. ( Hirabayashi, N; Ikeda, Y; Ishida, A; Matsuoka, S; Moriki, T; Okamoto, S; Wakui, M; Watanabe, R, 1998) |
| "We investigated whether adjusting the oral busulfan (BU) dosage on the basis of early pharmacokinetic data to achieve a targeted drug exposure could reduce transplant-related complications in children with advanced hematologic malignancies." | 3.70 | Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies. ( Chan, KW; Choroszy, M; Danielson, M; Felix, EA; Madden, T; Petropoulos, D; Przepiorka, D; Sprigg-Saenz, HA; Tran, HT; Worth, LL, 2000) |
| " Graft-versus-host disease (GVHD) prophylaxis consisted of T-cell depletion with IgM monoclonal antibody T10B9 plus complement and posttransplant cyclosporine-A." | 3.69 | Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia. ( Baxter-Lowe, LA; Bunin, N; Camitta, B; Casper, J; Garbrecht, F; Hunter, J; Lawton, C; Murray, K; Pietryga, D; Truitt, R, 1995) |
| "Twenty-five patients with hematologic malignancies were treated with busulfan (16 mg/kg) and cyclophosphamide (50 mg/kg x 3 days) as conditioning for bone marrow transplantation using marrow from serologically matched, DR locus genotypically identical unrelated donors." | 3.69 | Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only condition regimen. Low incidence of failed engraftment and severe acute GVHD. ( Brodsky, I; Bulova, S; Crilley, P; Marks, DI; Styler, MJ; Topolsky, D, 1996) |
| "Hepatic veno-occlusive disease (HVOD) is a frequent life-threatening toxicity in patients undergoing bone marrow transplantation (BMT) after the administration of a high-dose busulfan-containing regimen." | 3.69 | Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation. ( Boland, I; Challine, D; Deroussent, A; Gouyette, A; Hartmann, O; Koscielny, S; Lemerle, J; Valteau-Couanet, D; Vassal, G, 1996) |
| "Risk factors for hepatic veno-occlusive disease (HVOD) were analysed in a population of 136 autografted children who received high-dose busulfan (BU) as part of a conditioning regimen." | 3.68 | Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children. ( Benhamou, E; Brugieres, L; Hartmann, O; Lemerle, J; Méresse, V; Valteau-Couanet, D; Vassal, G, 1992) |
| "We performed a retrospective analysis of the incidence, risk factors, and clinical outcome of hepatic veno-occlusive disease (VOD) in 50 children prepared for bone marrow transplantation with busulfan (16 mg/kg) and cyclophosphamide (200 mg/kg)." | 3.68 | Hepatic veno-occlusive disease post-bone marrow transplantation in children conditioned with busulfan and cyclophosphamide: incidence, risk factors, and clinical outcome. ( Kohn, D; Lenarsky, C; Ozkaynak, MF; Parkman, R; Sender, L; Weinberg, K, 1991) |
| "Genotype-phenotype analyses of rare diseases often suffer from a lack of power, due to small sample size, which makes identifying significant associations difficult." | 3.30 | A novel integrative multi-omics approach to unravel the genetic determinants of rare diseases with application in sinusoidal obstruction syndrome. ( Ansari, M; Bittencourt, H; Dupanloup, I; Krajinovic, M; Kuehni, CE; Mlakar, SJ; Nava, T; Rezgui, MA; Waespe, N, 2023) |
| "Cumulative incidence of hepatic sinusoidal obstruction syndrome was 11%." | 2.77 | Phase II study of dose-modified busulfan by real-time targeting in allogeneic hematopoietic stem cell transplantation for myeloid malignancy. ( Atsuta, Y; Fukumoto, M; Inamoto, Y; Karasuno, T; Kohno, A; Kuwatsuka, Y; Miyamura, K; Morishita, Y; Murata, M; Nagafuji, K; Naoe, T; Saito, S; Sawa, M; Shimada, K; Suzuki, R; Taniguchi, S; Terakura, S; Yasuda, T, 2012) |
| "IVBu is a safe and effective and offers the benefit of predictable and consistent systemic exposure." | 2.75 | Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation. ( Chan, KW; Hayashi, RJ; Kadota, R; Kletzel, M; Mezzi, K; Nieder, ML; Przepiorka, D; Wall, DA; Yeager, AM, 2010) |
| "Thirty-six patients with advanced hematologic malignancies were treated." | 2.75 | Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. ( Artz, AS; Del Cerro, P; Godley, LA; Hart, J; Horowitz, S; Innocenti, F; Larson, RA; O'Donnell, PH; Odenike, OM; Pai, RK; Stock, W; Undevia, SD; Van Besien, K, 2010) |
| "Busulfan was combined with cyclophosphamide and melphalan (n=30), melphalan (n=27), and thiotepa (n=20)." | 2.73 | Elevated plasma ferritin and busulfan pharmacodynamics during high-dose chemotherapy regimens in children with malignant solid tumors. ( Benhamou, E; Bouligand, J; Drouard-Troalen, L; Grill, J; Hartmann, O; Le Maitre, A; Paci, A; Valteau-Couanet, D; Vassal, G, 2007) |
| " A dosage schedule based on body surface area should be used especially in young children to reduce the age-dependent difference in kinetics." | 2.70 | A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning. ( Aschan, J; Eber, S; Gungor, T; Hassan, M; Hassan, Z; Hentschke, P; Ljungman, P; Nilsson, C; Ringdén, O; Seger, R; Winiarski, J, 2002) |
| " The mean AUC, Css, Cmax and MRV were significantly higher in group B as compared with group A for both doses 1 and 13." | 2.69 | Pharmacokinetics of oral busulphan in children with beta thalassaemia major undergoing allogeneic bone marrow transplantation. ( Aigrain, EJ; Chandy, M; Dennison, D; Kanagasabapathy, AS; Krishnamoorthy, R; Poonkuzhali, B; Quernin, MH; Srivastava, A, 1999) |
| "Busulfan-treated patients had an increased risk of veno-occlusive disease (VOD) of the liver (12% v 1%, P =." | 2.69 | Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplanta ( Jacobsen, N; Lenhoff, S; Ljungman, P; Mellander, L; Nikoskelainen, J; Parkkali, T; Remberger, M; Ringdén, O; Ruutu, T; Sallerfors, B; Vindeløv, L; Volin, L, 1999) |
| "This meta-analysis was conducted to derive an integrated conclusion about the influence of glutathione S-transferase (GST) genetic polymorphisms on busulfan pharmacokinetic (PK) parameters and veno-occlusive disease (VOD)." | 2.61 | Effect of glutathione S-transferase genetic polymorphisms on busulfan pharmacokinetics and veno-occlusive disease in hematopoietic stem cell transplantation: A meta-analysis. ( Choi, B; Ji, E; Kim, K; Kim, MG; Kwak, A; Oh, JM, 2019) |
| " Getting more insight into the association between busulfan exposure and the development of VOD/SOS enables further optimization of dosing and treatment strategies." | 1.72 | Association Between the Magnitude of Intravenous Busulfan Exposure and Development of Hepatic Veno-Occlusive Disease in Children and Young Adults Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation. ( Ansari, M; Bartelink, IH; Bittencourt, H; Boelens, JJ; Bognàr, T; Bredius, RGM; Chiesa, R; Cowan, MJ; Cuvelier, GDE; Dvorak, C; Egberts, TCG; Güngör, T; Hassan, M; Hempel, G; Kletzel, M; Krajinovic, M; Lalmohamed, A; Long-Boyle, JR; Lund, T; Marktel, S; Nath, CE; Orchard, PJ; Rademaker, CMA; Savic, RM; Shaw, PJ; Slatter, MA; Théoret, Y; Versluys, AB; Wynn, RF, 2022) |
| " According to our single feature recommendation, following the busulfan dosage was the most effective for preventing VOD/SOS." | 1.72 | Prediction and recommendation by machine learning through repetitive internal validation for hepatic veno-occlusive disease/sinusoidal obstruction syndrome and early death after allogeneic hematopoietic cell transplantation. ( Cho, BS; Cho, SG; Eom, KS; Hwang, HJ; Jung, J; Kim, HJ; Kim, YJ; Lee, E; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, GJ; Park, MS; Park, S; Park, SS; Yoon, JH, 2022) |
| "Of those, 47% were transplanted for hematological malignancies and 53% for inherited hemoglobinopathies." | 1.56 | Busulfan clearance does not predict the development of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation. ( Al-Huneini, M; Al-Khabori, M; Al-Rawas, A; Al-Za'abi, M; Dennison, D; Salman, B, 2020) |
| "Secondary hemophagocytic syndrome (HPS) has been described after autologous hematopoietic cell transplant (AutoHCT)." | 1.51 | Secondary hemophagocytic syndrome after autologous hematopoietic cell transplant and immune therapy for neuroblastoma. ( Cervi, D; Epperly, R; Federico, S; Furman, W; Hines, M; Li, Y; Madden, R; Mamcarz, E; Santiago, T; Talleur, A; Triplett, B, 2019) |
| " These findings may have important implications for busulfan dosing and therapeutic drug monitoring practice in HSCT children." | 1.51 | Maximal concentration of intravenous busulfan as a determinant of veno-occlusive disease: a pharmacokinetic-pharmacodynamic analysis in 293 hematopoietic stem cell transplanted children. ( Bertrand, Y; Bleyzac, N; Goutelle, S; Neely, M; Philippe, M; Rushing, T, 2019) |
| "However, the effect of Gilbert's syndrome on the disposition of some drugs can lead to unexpected toxicity." | 1.43 | Mortality outcomes after busulfan-containing conditioning treatment and haemopoietic cell transplantation in patients with Gilbert's syndrome: a retrospective cohort study. ( Evans, AT; Gooley, TA; McCune, JS; McDonald, GB; Ostrow, JD; Schoch, G, 2016) |
| "We retrospectively analyzed 132 malignant lymphoma patients who underwent ASCT." | 1.43 | High pre-transplant serum ferritin and busulfan-thiotepa conditioning regimen as risk factors for hepatic sinusoidal obstructive syndrome after autologous stem cell transplantation in patients with malignant lymphoma. ( Cheong, JW; Hwang, DY; Jang, JE; Kim, JS; Kim, SJ; Kim, Y; Lee, JY; Min, YH; Yang, WI, 2016) |
| "Busulfan is a commonly used chemotherapeutic agent in myeloablative conditioning regimens for allogeneic hematopoietic cell transplantation (allo-HCT)." | 1.42 | Subacute hepatic necrosis mimicking veno-occlusive disease in a patient with HFE H63D homozygosity after allogeneic hematopoietic cell transplantation with busulfan conditioning. ( Boyer, MW; Chen, S; Chen, X; Hildebrandt, GC; McDonald, GB; Osborn, JD, 2015) |
| "Busulfan (Bu) is a DNA-alkylating agent used for myeloablative conditioning in stem cell transplantation in children and adults." | 1.40 | Evaluation of effects of busulfan and DMA on SOS in pediatric stem cell recipients. ( Bartelink, I; Boelens, J; Boos, J; Diestelhorst, C; Hempel, G; Kerl, K; Trame, MN, 2014) |
| "The new dosing schedule using IV Bu provides adequate therapeutic targeting from the first administration, with low toxicity and good disease control in high-risk children." | 1.38 | Weight-based strategy of dose administration in children using intravenous busulfan: clinical and pharmacokinetic results. ( Bertrand, Y; Bordigoni, P; Demeocq, F; Doz, F; Esperou, H; Frappaz, D; Galambrun, C; Gentet, JC; Méchinaud, F; Michel, G; Neven, B; Nguyen, L; Socié, G; Valteau-Couanet, D; Vassal, G; Yakouben, K, 2012) |
| "Most cases of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) occur <21 days after allogeneic hematopoietic stem cell transplant (HCT)." | 1.38 | Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant. ( Artz, AS; Hart, J; O'Donnell, PH; Pai, RK; van Besien, K, 2012) |
| "The patient was a 17-year-old male with acute myeloid leukemia in second complete remission." | 1.36 | [Usefulness of serum plasminogen activator inhibitor-1 for diagnosis and monitoring of late-onset sinusoidal obstruction syndrome after allogeneic stem cell transplantation]. ( Fujita, H; Ishigatsubo, Y; Ito, S; Kato, J; Nakaya, A; Ohata, M; Sano, A; Tachibana, T; Taguchi, J; Takemura, S, 2010) |
| "In order to assess the performance of Bayesian individualization of busulfan (BU) dosage regimens, veno-occlusive disease (VOD) rate was monitored for paediatric patients undergoing allogeneic bone marrow transplantation (BMT)." | 1.35 | Risk-adjusted monitoring of veno-occlusive disease following Bayesian individualization of busulfan dosage for bone marrow transplantation in paediatrics. ( Brice, K; Claire, G; Gilles, A; Nathalie, B; Valerie, B; Valerie, M; Yves, B, 2008) |
| " Pharmacokinetic parameters were estimated by using nonlinear mixed-effect modeling (NONMEM)." | 1.35 | Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients. ( Bartelink, IH; Boelens, JJ; Bredius, RG; den Hartigh, J; Guchelaar, HJ; Press, RR; van Derstraaten, TR; Zwaveling, J, 2008) |
| " Results of clinical outcome of previous studies performed to optimize busulfan and CsA therapy by controlling their pharmacokinetic variability by means of maximum a posteriori (MAP) Bayesian individualization of both drugs are presented." | 1.35 | The use of pharmacokinetic models in paediatric onco-haematology: effects on clinical outcome through the examples of busulfan and cyclosporine. ( Bleyzac, N, 2008) |
| "Busulfan is an example of a drug eliminated through glutathione S-transferase (GST)-catalyzed conjugation with reduced glutathione (GSH)." | 1.34 | Induction of glutathione synthesis explains pharmacodynamics of high-dose busulfan in mice and highlights putative mechanisms of drug interaction. ( Bouligand, J; Connault, E; Daudigeos, E; Deroussent, A; Morizet, J; Opolon, P; Paci, A; Re, M; Simonnard, N; Vassal, G, 2007) |
| "busulfan doses were adjusted to achieve a target AUC." | 1.34 | Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation. ( Doyle, J; Dupuis, LL; Finkelstein, Y; Koren, G; Moretti, M; Schechter, T; Verjee, Z, 2007) |
| "Hyperbilirubinemia was graded according to a report by Hogan et al (Blood." | 1.33 | Hepatic injury following reduced intensity unrelated cord blood transplantation for adult patients with hematological diseases. ( Fujiwara, M; Hori, A; Kami, M; Kanda, Y; Komatsu, T; Koyama, R; Kusumi, E; Masuoka, K; Matsumura, T; Miyakoshi, S; Murashige, N; Seki, K; Tanaka, Y; Taniguchi, S; Wake, A; Yuji, K, 2006) |
| "We studied the pharmacokinetics and clinical outcome of a new once-daily intravenous area under the curve-targeted dosing scheme for busulfan based on body surface area." | 1.33 | Once-daily intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ( Bredius, RG; den Hartigh, J; Egeler, RM; Guchelaar, HJ; Lankester, AC; Maarten Bredius, RG; Zwaveling, J, 2006) |
| "We studied the pharmacokinetics of intravenous busulfan (Bu) in children in order to further optimize intravenous Bu dosing in relation to toxicity and survival." | 1.33 | Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity. ( Ball, LM; Bredius, RG; Cremers, SC; den Hartigh, J; Egeler, RM; Lankester, AC; Teepe-Twiss, IM; Vossen, JM; Zwaveling, J, 2005) |
| " Previous work has suggested a cumulative dosage of 16 mg/kg for haematopoietic transplantation in children less than 3 years of age, but only limited data are available in infants." | 1.32 | Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results. ( Champagne, MA; Dalle, JH; Duval, M; Gardiner, J; Larocque, D; Shaw, L; Taylor, C; Theoret, Y; Vachon, MF; Wall, D, 2003) |
| "Patients with multiple myeloma (MM) and chronic renal failure have generally been excluded from myeloablative therapy programs followed by hematopoietic stem cell support because of the potential increase in transplant-related morbidity and mortality." | 1.31 | Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure. ( Benni, M; Cavo, M; Motta, MR; Rizzi, S; Ronconi, S; Tosi, P; Tura, S; Zamagni, E, 2000) |
| "Busulfan doses were decreased in 69% of patients compared to conventional doses." | 1.31 | Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. ( Aulagner, G; Bertrand, Y; Bleyzac, N; Dai, Q; Galambrun, C; Janoly, A; Jelliffe, RW; Magron, P; Maire, P; Martin, P; Souillet, G, 2001) |
| " Pharmacokinetic parameters in individual patients have been related to short-term toxicity and risk of relapse after HSCT." | 1.30 | Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation. ( Deeg, J; Ehninger, G; Ehrsam, M; Schmidt, H; Schneider, A; Schuler, US, 1998) |
| "Eighteen patients with poor risk Ewing's sarcoma (including 11 patients with metastatic disease at presentation) received consolidation therapy of busulphan and melphalan with autologous stem cell rescue." | 1.30 | High-dose busulphan/melphalan with autologous stem cell rescue in Ewing's sarcoma. ( Ashley, S; Atra, A; Calvagna, V; Pinkerton, CR; Shankar, AG; Shepherd, V; Souhami, RL; Whelan, JS, 1997) |
| " These patients received a total of 16 doses of busulfan dosed as 1 mg/kg/dose q 6 h beginning at 09." | 1.29 | Association of busulfan area under the curve with veno-occlusive disease following BMT. ( Davidson, TG; Devine, SM; Dix, SP; Geller, RB; Gilmore, CE; Heffner, LT; Hillyer, CD; Holland, HK; Jerkunica, I; Lin, LS; Mullins, RE; Saral, R; Wingard, JR; Winton, EF; York, RC, 1996) |
| " Busulfan was quantitated in plasma samples at 10 time points within the 6 h dosing interval using HPLC before and after dose numbers 1, 2, 5, 13 and 14." | 1.29 | Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted? ( Blanz, J; Ehninger, G; Kühnle, A; Kumbier, I; Mewes, K; Proksch, B; Schroer, S; Schuler, U; Zeller, KP, 1994) |
| "Busulfan is an alkylating agent that is widely used in preparative regimens for bone marrow transplantation (BMT)." | 1.28 | Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. ( Braine, HG; Brundrett, RB; Chen, TL; Colvin, OM; Grochow, LB; Jones, RJ; Santos, GW; Saral, R, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (4.69) | 18.7374 |
| 1990's | 38 (29.69) | 18.2507 |
| 2000's | 38 (29.69) | 29.6817 |
| 2010's | 36 (28.13) | 24.3611 |
| 2020's | 10 (7.81) | 2.80 |
| Authors | Studies |
|---|---|
| Bognàr, T | 1 |
| Bartelink, IH | 3 |
| Egberts, TCG | 1 |
| Rademaker, CMA | 1 |
| Versluys, AB | 1 |
| Slatter, MA | 1 |
| Kletzel, M | 3 |
| Nath, CE | 1 |
| Cuvelier, GDE | 1 |
| Savic, RM | 1 |
| Dvorak, C | 1 |
| Long-Boyle, JR | 1 |
| Cowan, MJ | 1 |
| Bittencourt, H | 4 |
| Bredius, RGM | 2 |
| Güngör, T | 2 |
| Shaw, PJ | 1 |
| Ansari, M | 4 |
| Hassan, M | 4 |
| Krajinovic, M | 4 |
| Hempel, G | 3 |
| Marktel, S | 2 |
| Chiesa, R | 2 |
| Théoret, Y | 3 |
| Lund, T | 1 |
| Orchard, PJ | 1 |
| Wynn, RF | 1 |
| Boelens, JJ | 3 |
| Lalmohamed, A | 1 |
| Lee, S | 2 |
| Lee, E | 1 |
| Park, SS | 1 |
| Park, MS | 1 |
| Jung, J | 1 |
| Min, GJ | 1 |
| Park, S | 1 |
| Lee, SE | 1 |
| Cho, BS | 1 |
| Eom, KS | 1 |
| Kim, YJ | 1 |
| Kim, HJ | 1 |
| Min, CK | 1 |
| Cho, SG | 1 |
| Lee, JW | 1 |
| Hwang, HJ | 1 |
| Yoon, JH | 1 |
| Waespe, N | 1 |
| Mlakar, SJ | 1 |
| Dupanloup, I | 1 |
| Rezgui, MA | 3 |
| Kuehni, CE | 1 |
| Nava, T | 2 |
| Ma, X | 1 |
| Yuan, J | 1 |
| Liu, X | 1 |
| Xu, J | 1 |
| Han, J | 1 |
| Wang, X | 1 |
| Zhao, L | 1 |
| Epperly, R | 1 |
| Furman, W | 1 |
| Hines, M | 1 |
| Santiago, T | 1 |
| Li, Y | 2 |
| Madden, R | 1 |
| Mamcarz, E | 1 |
| Cervi, D | 1 |
| Federico, S | 1 |
| Triplett, B | 1 |
| Talleur, A | 1 |
| Terakura, S | 2 |
| Onizuka, M | 1 |
| Fukumoto, M | 2 |
| Kuwatsuka, Y | 2 |
| Kohno, A | 2 |
| Ozawa, Y | 1 |
| Miyamura, K | 2 |
| Inagaki, Y | 1 |
| Sawa, M | 2 |
| Atsuta, Y | 2 |
| Suzuki, R | 2 |
| Naoe, T | 2 |
| Morishita, Y | 2 |
| Murata, M | 2 |
| El-Serafi, I | 1 |
| Remberger, M | 3 |
| Ringdèn, O | 5 |
| Törlén, J | 1 |
| Sundin, M | 1 |
| Björklund, A | 1 |
| Winiarski, J | 3 |
| Mattsson, J | 1 |
| Petrykey, K | 1 |
| Del Vecchio, V | 1 |
| Cortyl, J | 1 |
| Ralph, RO | 1 |
| Beaulieu, P | 1 |
| St-Onge, P | 1 |
| Jurkovic Mlakar, S | 1 |
| Huezo-Diaz Curtis, P | 2 |
| Uppugunduri, CRS | 2 |
| Lesne, L | 1 |
| Chalandon, Y | 1 |
| Dalle, JH | 2 |
| Lewis, V | 1 |
| Kangarloo, BS | 1 |
| Peters, C | 2 |
| Sinnett, D | 1 |
| Salman, B | 1 |
| Al-Khabori, M | 1 |
| Al-Huneini, M | 1 |
| Al-Rawas, A | 1 |
| Dennison, D | 2 |
| Al-Za'abi, M | 1 |
| Esteves, I | 1 |
| Santos, FPS | 1 |
| Ribeiro, AAF | 1 |
| Seber, A | 1 |
| Sugawara, EK | 1 |
| Sobrinho, JJDN | 1 |
| Barros, JC | 1 |
| Oliveira, JSR | 1 |
| Fernandes, JF | 1 |
| Hamerschlak, N | 1 |
| Andersson, BS | 2 |
| de Lima, M | 1 |
| Kerbauy, FR | 1 |
| Jain, R | 1 |
| Gupta, K | 1 |
| Bhatia, A | 1 |
| Bansal, A | 1 |
| Bansal, D | 1 |
| Abate, ME | 1 |
| Paioli, A | 1 |
| Cammelli, S | 1 |
| Cesari, M | 1 |
| Longhi, A | 1 |
| Palmerini, E | 1 |
| Ferrari, S | 1 |
| Carretta, E | 1 |
| Picci, P | 1 |
| Piscaglia, F | 1 |
| Qin, CJ | 1 |
| Liu, LJ | 1 |
| Zhang, ZM | 1 |
| Luo, L | 1 |
| Lai, YR | 1 |
| Li, QC | 1 |
| Philippe, M | 1 |
| Neely, M | 1 |
| Rushing, T | 1 |
| Bertrand, Y | 3 |
| Bleyzac, N | 3 |
| Goutelle, S | 1 |
| Schechter, T | 2 |
| Perez-Albuerne, E | 1 |
| Lin, TF | 1 |
| Irwin, MS | 1 |
| Essa, M | 1 |
| Desai, AV | 2 |
| Frangoul, H | 1 |
| Yanik, G | 1 |
| Dupuis, LL | 2 |
| Jacobsohn, D | 1 |
| Ranalli, M | 1 |
| Soni, S | 1 |
| Seif, AE | 2 |
| Grupp, S | 1 |
| Dvorak, CC | 1 |
| Kanda, Y | 3 |
| Kim, MG | 1 |
| Kwak, A | 1 |
| Choi, B | 1 |
| Ji, E | 1 |
| Oh, JM | 1 |
| Kim, K | 1 |
| Lee, CC | 1 |
| Chang, HH | 1 |
| Lu, MY | 1 |
| Yang, YL | 1 |
| Chou, SW | 1 |
| Lin, DT | 1 |
| Jou, ST | 1 |
| Yao, M | 1 |
| Li, CC | 1 |
| Yeh, SP | 1 |
| Chen, MH | 1 |
| Gau, JP | 1 |
| Li, SS | 1 |
| Wang, PN | 1 |
| Liu, YC | 1 |
| Wang, TF | 1 |
| Tan, TD | 1 |
| Lee, MY | 1 |
| Yu, MS | 1 |
| Wang, CC | 1 |
| Lin, SC | 1 |
| Chen, YC | 1 |
| Su, YC | 1 |
| Su, KY | 1 |
| Lin, KH | 1 |
| Rezvani, AR | 1 |
| McCune, JS | 3 |
| Storer, BE | 1 |
| Batchelder, A | 1 |
| Kida, A | 1 |
| Deeg, HJ | 2 |
| McDonald, GB | 4 |
| Mathews, V | 2 |
| George, B | 2 |
| Viswabandya, A | 1 |
| Abraham, A | 1 |
| Ahmed, R | 1 |
| Ganapule, A | 1 |
| Sindhuvi, E | 1 |
| Lakshmi, KM | 1 |
| Srivastava, A | 3 |
| Valteau-Couanet, D | 9 |
| Le Deley, MC | 1 |
| Bergeron, C | 1 |
| Ducassou, S | 1 |
| Michon, J | 1 |
| Rubie, H | 1 |
| Le Teuff, G | 1 |
| Coze, C | 1 |
| Plantaz, D | 1 |
| Sirvent, N | 1 |
| Bouzy, J | 1 |
| Chastagner, P | 1 |
| Hartmann, O | 12 |
| Gökce, M | 1 |
| Kuskonmaz, B | 1 |
| Cetin, M | 1 |
| Uckan Cetinkaya, D | 1 |
| Tuncer, M | 1 |
| Kerl, K | 1 |
| Diestelhorst, C | 1 |
| Bartelink, I | 1 |
| Boelens, J | 1 |
| Trame, MN | 1 |
| Boos, J | 2 |
| Nagler, A | 1 |
| Labopin, M | 1 |
| Berger, R | 1 |
| Bunjes, D | 1 |
| Campos, A | 1 |
| Socié, G | 2 |
| Kröger, N | 2 |
| Goker, H | 1 |
| Yakoub-Agha, I | 1 |
| Shimoni, A | 1 |
| Mohty, M | 1 |
| Rocha, V | 1 |
| Efrati, E | 1 |
| Zuckerman, T | 1 |
| Ben-Ami, E | 1 |
| Krivoy, N | 1 |
| Qiao, J | 1 |
| Fu, J | 1 |
| Fang, T | 1 |
| Huang, Y | 1 |
| Mi, H | 1 |
| Yang, N | 1 |
| Chen, C | 1 |
| Xu, K | 1 |
| Zeng, L | 1 |
| Berger, K | 1 |
| Schopohl, D | 1 |
| Rieger, C | 1 |
| Ostermann, H | 1 |
| Hwang, DY | 1 |
| Kim, SJ | 2 |
| Cheong, JW | 1 |
| Kim, Y | 1 |
| Jang, JE | 1 |
| Lee, JY | 1 |
| Min, YH | 1 |
| Yang, WI | 1 |
| Kim, JS | 1 |
| Chen, S | 1 |
| Osborn, JD | 1 |
| Chen, X | 1 |
| Boyer, MW | 1 |
| Hildebrandt, GC | 1 |
| De La Serna, J | 1 |
| Sanz, J | 1 |
| Bermúdez, A | 1 |
| Cabrero, M | 1 |
| Serrano, D | 1 |
| Vallejo, C | 1 |
| Gómez, V | 1 |
| Moraleda, JM | 1 |
| Perez, SG | 1 |
| Caballero, MD | 1 |
| Conde, E | 1 |
| Lahuerta, JJ | 2 |
| Sanz, G | 1 |
| Pasquini, MC | 1 |
| Le-Rademacher, J | 1 |
| Zhu, X | 1 |
| Artz, A | 1 |
| DiPersio, J | 1 |
| Fernandez, HF | 1 |
| Mineishi, S | 1 |
| Kamishohara, M | 1 |
| Mehta, J | 1 |
| Nakamura, Y | 1 |
| Ratanatharathorn, V | 1 |
| Sobecks, R | 1 |
| Burkart, J | 1 |
| Bredeson, C | 1 |
| Heneghan, MB | 1 |
| Bunin, NJ | 1 |
| Grupp, SA | 1 |
| Bagatell, R | 1 |
| Floeter, AE | 1 |
| Volin, L | 3 |
| Niittyvuopio, R | 1 |
| Heiskanen, J | 1 |
| Lindström, V | 1 |
| Nihtinen, A | 1 |
| Sahlstedt, L | 1 |
| Ruutu, T | 3 |
| Muthukumaran, J | 1 |
| Bader, P | 1 |
| Duval, M | 2 |
| Evans, AT | 1 |
| Schoch, G | 1 |
| Ostrow, JD | 1 |
| Gooley, TA | 1 |
| Cacchione, A | 1 |
| LeMaitre, A | 1 |
| Couanet, DV | 1 |
| Benhamou, E | 6 |
| Amoroso, L | 1 |
| Simonnard, N | 2 |
| Zwaveling, J | 3 |
| Press, RR | 1 |
| Bredius, RG | 3 |
| van Derstraaten, TR | 1 |
| den Hartigh, J | 3 |
| Guchelaar, HJ | 2 |
| Wall, DA | 1 |
| Chan, KW | 2 |
| Nieder, ML | 1 |
| Hayashi, RJ | 1 |
| Yeager, AM | 1 |
| Kadota, R | 1 |
| Przepiorka, D | 3 |
| Mezzi, K | 1 |
| Cappelli, B | 1 |
| Evangelio, C | 1 |
| Biffi, A | 1 |
| Roccia, T | 1 |
| Frugnoli, I | 1 |
| Biral, E | 1 |
| Noè, A | 1 |
| Fossati, M | 1 |
| Finizio, V | 1 |
| Miniero, R | 1 |
| Napolitano, S | 1 |
| Ferrua, F | 1 |
| Soliman, C | 1 |
| Ciceri, F | 1 |
| Roncarolo, MG | 1 |
| Lee, SC | 1 |
| Lee, DH | 1 |
| Kim, WS | 1 |
| Suh, C | 1 |
| Won, JH | 1 |
| Ulrickson, M | 1 |
| Aldridge, J | 1 |
| Kim, HT | 1 |
| Hochberg, EP | 1 |
| Hammerman, P | 1 |
| Dube, C | 1 |
| Attar, E | 1 |
| Ballen, KK | 1 |
| Dey, BR | 1 |
| McAfee, SL | 1 |
| Spitzer, TR | 1 |
| Chen, YB | 1 |
| Ito, S | 1 |
| Taguchi, J | 1 |
| Kato, J | 1 |
| Nakaya, A | 1 |
| Tachibana, T | 1 |
| Takemura, S | 1 |
| Sano, A | 1 |
| Ohata, M | 1 |
| Ishigatsubo, Y | 1 |
| Fujita, H | 1 |
| Cantoni, N | 1 |
| Gerull, S | 1 |
| Heim, D | 1 |
| Halter, J | 1 |
| Bucher, C | 1 |
| Buser, A | 1 |
| Tsakiris, DA | 1 |
| Passweg, J | 1 |
| Tichelli, A | 1 |
| Stern, M | 1 |
| Gratwohl, A | 1 |
| O'Donnell, PH | 2 |
| Artz, AS | 2 |
| Undevia, SD | 1 |
| Pai, RK | 2 |
| Del Cerro, P | 1 |
| Horowitz, S | 1 |
| Godley, LA | 1 |
| Hart, J | 2 |
| Innocenti, F | 1 |
| Larson, RA | 1 |
| Odenike, OM | 1 |
| Stock, W | 1 |
| Van Besien, K | 3 |
| Michel, G | 1 |
| Gentet, JC | 1 |
| Esperou, H | 1 |
| Méchinaud, F | 1 |
| Doz, F | 1 |
| Neven, B | 1 |
| Galambrun, C | 2 |
| Demeocq, F | 1 |
| Yakouben, K | 1 |
| Bordigoni, P | 1 |
| Frappaz, D | 1 |
| Nguyen, L | 1 |
| Vassal, G | 10 |
| Jia, L | 1 |
| Yan, ZL | 1 |
| Xu, SJ | 1 |
| Xu, KL | 1 |
| Zeng, LY | 1 |
| Reimer, J | 1 |
| Bien, S | 1 |
| Ameling, S | 1 |
| Hammer, E | 1 |
| Völker, U | 1 |
| Kroemer, HK | 2 |
| Ritter, CA | 2 |
| Saito, S | 1 |
| Shimada, K | 1 |
| Yasuda, T | 1 |
| Inamoto, Y | 1 |
| Karasuno, T | 1 |
| Taniguchi, S | 2 |
| Nagafuji, K | 1 |
| Lassau, N | 2 |
| Auperin, A | 3 |
| Leclere, J | 2 |
| Bennaceur, A | 1 |
| Lee, JH | 6 |
| Lee, KH | 3 |
| Kim, S | 1 |
| Seol, M | 2 |
| Park, CJ | 2 |
| Chi, HS | 2 |
| Kang, W | 1 |
| Kim, ST | 1 |
| Kim, WK | 2 |
| Lee, JS | 2 |
| Grochow, LB | 2 |
| Kashyap, A | 1 |
| Wingard, J | 1 |
| Cagnoni, P | 1 |
| Roy, J | 1 |
| Tarantolo, S | 1 |
| Hu, W | 1 |
| Blume, K | 1 |
| Niland, J | 1 |
| Palmer, JM | 1 |
| Vaughan, W | 1 |
| Fernandez, H | 1 |
| Champlin, R | 2 |
| Forman, S | 1 |
| Nilsson, C | 2 |
| Hassan, Z | 1 |
| Aschan, J | 1 |
| Hentschke, P | 1 |
| Eber, S | 1 |
| Seger, R | 1 |
| Ljungman, P | 3 |
| Slattery, JT | 1 |
| Dressel, D | 1 |
| Sperker, B | 1 |
| Grube, M | 1 |
| Maier, T | 1 |
| Klingebiel, T | 1 |
| Siegmund, W | 1 |
| Beck, JF | 1 |
| Wall, D | 1 |
| Shaw, L | 1 |
| Larocque, D | 1 |
| Taylor, C | 1 |
| Gardiner, J | 1 |
| Vachon, MF | 1 |
| Champagne, MA | 1 |
| Bouligand, J | 4 |
| Boland, I | 3 |
| Deroussent, A | 5 |
| Kalifa, C | 2 |
| Poonkuzhali, B | 2 |
| Shaji, RV | 1 |
| Chandy, M | 2 |
| Krishnamoorthy, R | 2 |
| Cremers, SC | 1 |
| Ball, LM | 1 |
| Lankester, AC | 2 |
| Teepe-Twiss, IM | 1 |
| Egeler, RM | 2 |
| Vossen, JM | 1 |
| Choi, SJ | 2 |
| Kim, SE | 1 |
| Lee, MS | 3 |
| Lapierre, V | 1 |
| Mahé, C | 1 |
| Stambouli, F | 1 |
| Oubouzar, N | 1 |
| Tramalloni, D | 1 |
| Tiberghien, P | 1 |
| Clopés, A | 1 |
| Sureda, A | 1 |
| Sierra, J | 1 |
| Queraltó, JM | 1 |
| Broto, A | 1 |
| Farré, R | 1 |
| Moreno, E | 1 |
| Brunet, S | 2 |
| Martino, R | 1 |
| Mangues, MA | 1 |
| Maarten Bredius, RG | 1 |
| Opolon, P | 1 |
| Morizet, J | 1 |
| Connault, E | 1 |
| Daudigeos, E | 1 |
| Re, M | 1 |
| Paci, A | 3 |
| Kusumi, E | 1 |
| Kami, M | 1 |
| Murashige, N | 1 |
| Seki, K | 1 |
| Fujiwara, M | 1 |
| Koyama, R | 1 |
| Komatsu, T | 1 |
| Hori, A | 1 |
| Tanaka, Y | 1 |
| Yuji, K | 1 |
| Matsumura, T | 1 |
| Masuoka, K | 1 |
| Wake, A | 1 |
| Miyakoshi, S | 1 |
| Rodriguez, R | 1 |
| Nademanee, A | 1 |
| Ruel, N | 1 |
| Smith, E | 1 |
| Krishnan, A | 1 |
| Popplewell, L | 1 |
| Zain, J | 1 |
| Patane, K | 1 |
| Kogut, N | 1 |
| Nakamura, R | 1 |
| Sarkodee-Adoo, C | 1 |
| Forman, SJ | 1 |
| Finkelstein, Y | 1 |
| Doyle, J | 1 |
| Verjee, Z | 1 |
| Moretti, M | 1 |
| Koren, G | 1 |
| Le Maitre, A | 1 |
| Grill, J | 1 |
| Drouard-Troalen, L | 1 |
| Chen, J | 1 |
| Zhu, KE | 1 |
| Zhang, T | 1 |
| Zhong, J | 1 |
| Chen, ST | 1 |
| Zeng, HL | 1 |
| Ryu, SG | 1 |
| Lee, YS | 1 |
| Hur, EH | 1 |
| Lee, SH | 1 |
| Bae, KS | 1 |
| Noh, GJ | 1 |
| Yun, SC | 1 |
| Han, SB | 1 |
| Couvreur, P | 1 |
| Layre, AM | 1 |
| Delain, E | 1 |
| Gref, R | 1 |
| Brice, K | 1 |
| Valerie, B | 1 |
| Claire, G | 1 |
| Valerie, M | 1 |
| Yves, B | 1 |
| Gilles, A | 1 |
| Nathalie, B | 1 |
| Carreras, E | 1 |
| Rosiñol, L | 1 |
| Terol, MJ | 1 |
| Alegre, A | 1 |
| de Arriba, F | 1 |
| García-Laraña, J | 1 |
| Bello, JL | 1 |
| García, R | 1 |
| León, A | 1 |
| Martínez, R | 1 |
| Peñarrubia, MJ | 1 |
| Poderós, C | 1 |
| Ribas, P | 1 |
| Ribera, JM | 1 |
| San Miguel, J | 1 |
| Bladé, J | 1 |
| Mellgren, K | 1 |
| Fasth, A | 1 |
| Abrahamsson, J | 1 |
| Qureshi, A | 1 |
| Marshall, L | 1 |
| Lancaster, D | 1 |
| Castenskiold, EC | 1 |
| Kelsey, SM | 1 |
| Collins, PW | 1 |
| Coldwell, RD | 1 |
| Allen, PD | 1 |
| Side, LE | 1 |
| Makin, HL | 1 |
| Goldstone, AH | 1 |
| Newland, AC | 1 |
| Casper, J | 1 |
| Camitta, B | 1 |
| Truitt, R | 1 |
| Baxter-Lowe, LA | 1 |
| Bunin, N | 1 |
| Lawton, C | 1 |
| Murray, K | 1 |
| Hunter, J | 1 |
| Pietryga, D | 1 |
| Garbrecht, F | 1 |
| Klingemann, HG | 1 |
| Shepherd, JD | 1 |
| Reece, DE | 1 |
| Barnett, MJ | 1 |
| Nantel, SH | 1 |
| Sutherland, HJ | 1 |
| Spinelli, JJ | 1 |
| Phillips, GL | 1 |
| Bearman, SI | 1 |
| Schuler, U | 1 |
| Schroer, S | 1 |
| Kühnle, A | 1 |
| Blanz, J | 1 |
| Mewes, K | 1 |
| Kumbier, I | 1 |
| Proksch, B | 1 |
| Zeller, KP | 1 |
| Ehninger, G | 2 |
| Bandini, G | 1 |
| Belardinelli, A | 1 |
| Rosti, G | 1 |
| Calori, E | 1 |
| Motta, MR | 2 |
| Rizzi, S | 2 |
| Benini, C | 1 |
| Tura, S | 2 |
| Nikoskelainen, J | 2 |
| Vindeløv, L | 2 |
| Parkkali, T | 2 |
| Lenhoff, S | 2 |
| Sallerfors, B | 2 |
| Stockschläder, M | 1 |
| Kalhs, P | 1 |
| Peters, S | 1 |
| Zeller, W | 1 |
| Krüger, W | 2 |
| Kabisch, H | 2 |
| Lechner, K | 1 |
| Zander, A | 1 |
| Challine, D | 2 |
| Koscielny, S | 2 |
| Lemerle, J | 4 |
| Lévi, F | 1 |
| Gouyette, A | 2 |
| Akiyama, H | 1 |
| Tanikawa, S | 1 |
| Sakamaki, H | 1 |
| Sasaki, T | 1 |
| Takamoto, S | 1 |
| Onozawa, Y | 1 |
| Dix, SP | 1 |
| Wingard, JR | 1 |
| Mullins, RE | 1 |
| Jerkunica, I | 1 |
| Davidson, TG | 1 |
| Gilmore, CE | 1 |
| York, RC | 1 |
| Lin, LS | 1 |
| Devine, SM | 1 |
| Geller, RB | 1 |
| Heffner, LT | 1 |
| Hillyer, CD | 1 |
| Holland, HK | 1 |
| Winton, EF | 1 |
| Saral, R | 2 |
| Topolsky, D | 3 |
| Crilley, P | 3 |
| Styler, MJ | 2 |
| Bulova, S | 2 |
| Brodsky, I | 3 |
| Marks, DI | 2 |
| Biggs, J | 3 |
| Moul, J | 1 |
| Copelan, E | 1 |
| Avalos, B | 1 |
| Penza, S | 1 |
| Sabol, P | 1 |
| Downs, K | 2 |
| Szer, J | 2 |
| Bourhis, JH | 1 |
| Bosq, J | 1 |
| Ibrahim, A | 1 |
| Girinski, T | 1 |
| Pico, JL | 1 |
| Roche, A | 1 |
| Atra, A | 1 |
| Whelan, JS | 1 |
| Calvagna, V | 1 |
| Shankar, AG | 1 |
| Ashley, S | 1 |
| Shepherd, V | 1 |
| Souhami, RL | 1 |
| Pinkerton, CR | 1 |
| Morris, JD | 1 |
| Harris, RE | 1 |
| Hashmi, R | 1 |
| Sambrano, JE | 1 |
| Gruppo, RA | 1 |
| Becker, AT | 1 |
| Morris, CL | 1 |
| Matsuoka, S | 1 |
| Okamoto, S | 1 |
| Ishida, A | 1 |
| Wakui, M | 1 |
| Watanabe, R | 1 |
| Moriki, T | 1 |
| Ikeda, Y | 1 |
| Hirabayashi, N | 1 |
| Sonneveld, P | 1 |
| Laméris, JS | 1 |
| Cornelissen, J | 1 |
| Ogilvie, A | 1 |
| Löwenberg, B | 1 |
| Essell, JH | 2 |
| Schroeder, MT | 1 |
| Harman, GS | 2 |
| Halvorson, R | 1 |
| Lew, V | 1 |
| Callander, N | 1 |
| Snyder, M | 1 |
| Lewis, SK | 1 |
| Allerton, JP | 1 |
| Thompson, JM | 2 |
| Schuler, US | 1 |
| Ehrsam, M | 1 |
| Schneider, A | 1 |
| Schmidt, H | 1 |
| Deeg, J | 1 |
| Mellander, L | 1 |
| Jacobsen, N | 1 |
| Khouri, I | 1 |
| Thall, P | 1 |
| Mehra, R | 1 |
| Ippoliti, C | 1 |
| Giralt, S | 1 |
| Gajewski, J | 1 |
| Andersson, B | 1 |
| Körbling, M | 1 |
| Deisseroth, AB | 1 |
| Quernin, MH | 1 |
| Aigrain, EJ | 1 |
| Kanagasabapathy, AS | 1 |
| Lee, JL | 1 |
| Gooley, T | 1 |
| Bensinger, W | 1 |
| Schiffman, K | 1 |
| Tosi, P | 1 |
| Zamagni, E | 1 |
| Ronconi, S | 1 |
| Benni, M | 1 |
| Cavo, M | 1 |
| Tran, HT | 1 |
| Madden, T | 1 |
| Petropoulos, D | 1 |
| Worth, LL | 1 |
| Felix, EA | 1 |
| Sprigg-Saenz, HA | 1 |
| Choroszy, M | 1 |
| Danielson, M | 1 |
| Copelan, EA | 2 |
| Penza, SL | 2 |
| Theil, KS | 1 |
| Elder, PJ | 2 |
| Bechtel, TP | 2 |
| Tighe, MB | 1 |
| Ezzone, SA | 2 |
| Scholl, MD | 2 |
| Belt, PS | 1 |
| Young, DC | 1 |
| Avalos, BR | 2 |
| Schetelig, J | 1 |
| Zabelina, T | 1 |
| Renges, H | 1 |
| Stute, N | 1 |
| Schrum, J | 1 |
| Siegert, W | 1 |
| Zander, AR | 1 |
| Souillet, G | 1 |
| Magron, P | 1 |
| Janoly, A | 1 |
| Martin, P | 1 |
| Dai, Q | 1 |
| Maire, P | 1 |
| Jelliffe, RW | 1 |
| Aulagner, G | 1 |
| Kasai, M | 1 |
| Kiyama, Y | 1 |
| Watanabe, M | 1 |
| Seto, K | 1 |
| Matsuura, A | 1 |
| Tanaka, J | 1 |
| Takeda, H | 1 |
| Naohara, T | 1 |
| Higa, T | 1 |
| Hashino, S | 1 |
| Méresse, V | 1 |
| Brugieres, L | 2 |
| Halvorson, RD | 1 |
| Snyder, MJ | 1 |
| Johnson, RA | 1 |
| Rubinsak, JR | 1 |
| Epstein, RB | 1 |
| Min, KW | 1 |
| Anderson, SL | 1 |
| Syzek, L | 1 |
| Loiseau, HA | 1 |
| Valteau, D | 1 |
| McDowell, H | 1 |
| Patte, C | 1 |
| Vaughan, WP | 1 |
| Dennison, JD | 1 |
| Reed, EC | 1 |
| Klassen, L | 1 |
| McGuire, TR | 1 |
| Sanger, WG | 1 |
| Kumar, PP | 1 |
| Warkentin, PI | 1 |
| Gordon, BG | 1 |
| Bierman, PJ | 1 |
| Collins, P | 1 |
| Jones, B | 1 |
| Uthayakumar, S | 1 |
| Pocock, C | 1 |
| Jupp, R | 1 |
| Gutteridge, G | 1 |
| Chopra, R | 1 |
| Blare, S | 1 |
| Newland, A | 1 |
| Ozkaynak, MF | 1 |
| Weinberg, K | 1 |
| Kohn, D | 1 |
| Sender, L | 1 |
| Parkman, R | 1 |
| Lenarsky, C | 1 |
| Morgan, M | 1 |
| Dodds, A | 2 |
| Atkinson, K | 2 |
| Zuazu, I | 1 |
| Fernández, MT | 1 |
| Domingo-Albós, A | 1 |
| Brodsky, R | 1 |
| Jones, RJ | 1 |
| Brundrett, RB | 1 |
| Braine, HG | 1 |
| Chen, TL | 1 |
| Santos, GW | 1 |
| Colvin, OM | 1 |
| Snover, DC | 1 |
| Weisdorf, S | 1 |
| Bloomer, J | 1 |
| McGlave, P | 1 |
| Weisdorf, D | 1 |
| Peters, WG | 1 |
| Shulman, HM | 2 |
| Luk, K | 1 |
| Shuman, WB | 1 |
| Storb, R | 2 |
| Kanfer, EJ | 1 |
| Buckner, CD | 1 |
| Fefer, A | 1 |
| Appelbaum, FR | 1 |
| Hill, RS | 1 |
| Amos, D | 1 |
| Doney, KC | 1 |
| Clift, RA | 1 |
| Noble, G | 1 |
| Ashby, M | 1 |
| Concannon, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Polymorphisms and Busulfan Pharmacokinetic Study in Pediatric Transplnatation[NCT01257854] | 200 participants (Anticipated) | Observational | 2008-02-29 | Recruiting | |||
| Cyclophosphamide-Busulfan Versus Busulfan-Cyclophosphamide as Conditioning Regimen Before Allogeneic Hematopoietic Stem Cell Transplantation for Leukemia: a Prospective Randomized Study to Assess Liver Toxicity[NCT01779882] | 72 participants (Actual) | Interventional | 2013-01-31 | Completed | |||
| A Phase I-II Study of Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies[NCT00943319] | Phase 1/Phase 2 | 50 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| A Retrospective Study About Detection of Sinusoidal Obstruction Syndrome With Ultrasound After Allogeneic Hematopoietic Stem Cell Transplantation[NCT04141735] | 114 participants (Actual) | Observational | 2016-09-30 | Completed | |||
| Usefulness of Liver Stiffness Measurement in Predicting Hepatic Veno-Occlusive Disease Development in Patients Who Undergo HSCT: a Multicentric Prospective Study[NCT03426358] | 1,101 participants (Actual) | Interventional | 2015-04-28 | Completed | |||
| Revisiting the Universal Donor: Does Exposure to O Blood Products Affect Patient Outcomes[NCT04859218] | 30 participants (Anticipated) | Interventional | 2023-11-30 | Recruiting | |||
| Safety and Efficacy of Ibritumomab Tiuxetan (Zevalin®) in Association With a Fludarabine Based Reduced Conditioning Regimen and Allogenic Stem Cell Support in Chemo-sensitive Relapsed CD20 Positive Aggressive Non-Hodgkin's Lymphoma Patients.[NCT00607854] | Phase 2 | 31 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| A Phase 2, Open-label, Prospective, Multicenter Study to Evaluate the Efficacy of Intravenous Busulfan and Melphalan as a Conditioning Regimen in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation[NCT01923935] | Phase 2 | 105 participants (Anticipated) | Interventional | 2013-01-31 | Recruiting | ||
| The Therapeutic Window of Busulfan in Children With Haemopoietic Stem Cell Transplantation：A Multicenter Study in China[NCT04786002] | 500 participants (Anticipated) | Observational | 2020-11-01 | Recruiting | |||
| Validating Ultrasound Biomarkers for Hepatic Sinusoidal Obstruction Syndrome in Pediatric Hematopoietic Cell Transplant Patients[NCT03963999] | Phase 4 | 0 participants (Actual) | Interventional | 2020-04-01 | Withdrawn (stopped due to We did not receive grant funding. We will reapply in June of 2020) | ||
| Non-Myeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Chronic Phase CML[NCT00001144] | Phase 2 | 50 participants | Interventional | 1999-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Disease Free Survival measured by median survival time in days (NCT00943319)
Timeframe: 5 years
| Intervention | days (Median) |
|---|---|
| Busulfan and Fludarabine | 172 |
Maximally tolerated area under the curve of intravenous busulfan (Busulfan®) in combination with fludarabine as conditioning regimen for transplantation with in-vivo T-cell depletion. The number reported will be an Area Under the Curve (AUC) measure reported in µmol-min/L. (NCT00943319)
Timeframe: 5 years
| Intervention | mmol-min/L (Number) |
|---|---|
| Busulfan and Fludarabine | 6800 |
Overall Survival measured as median survival in days (NCT00943319)
Timeframe: 5 years
| Intervention | days (Median) |
|---|---|
| Busulfan and Fludarabine | 161 |
3 reviews available for busulfan and Hepatic Veno Occlusive Disease
| Article | Year |
|---|---|
Effect of glutathione S-transferase genetic polymorphisms on busulfan pharmacokinetics and veno-occlusive disease in hematopoietic stem cell transplantation: A meta-analysis.
Topics: Adolescent; Adult; Aged; Busulfan; Child; Child, Preschool; Glutathione Transferase; Hematopoietic S | 2019 |
Regimen-related acute toxicities: pathophysiology, risk factors, clinical evaluation and preventive strategies.
Topics: Acute Disease; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Tr | 1994 |
The role of busulfan in bone marrow transplantation.
Topics: Adult; Age Factors; Animals; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Hepatic | 1999 |
28 trials available for busulfan and Hepatic Veno Occlusive Disease
| Article | Year |
|---|---|
A novel integrative multi-omics approach to unravel the genetic determinants of rare diseases with application in sinusoidal obstruction syndrome.
Topics: Busulfan; Genome-Wide Association Study; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlu | 2023 |
Analysis of glutathione S-transferase and cytochrome P450 gene polymorphism in recipients of dose-adjusted busulfan-cyclophosphamide conditioning.
Topics: Adult; Aged; Alleles; Area Under Curve; Busulfan; Cyclophosphamide; Cytochrome P-450 Enzyme System; | 2020 |
Is pharmacokinetic guidance a must in busulfan regimens?
Topics: Area Under Curve; Busulfan; Cyclophosphamide; Female; Graft Rejection; Hematopoietic Stem Cell Trans | 2018 |
The incidence and risk factors of hepatic veno-occlusive disease after hematopoietic stem cell transplantation in Taiwan.
Topics: Adolescent; Adult; Allografts; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Female; Hemato | 2019 |
Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes.
Topics: Adult; Aged; Busulfan; Case-Control Studies; Cyclophosphamide; Drug Administration Schedule; Hematop | 2013 |
Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy.
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Prescho | 2014 |
Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS.
Topics: Adult; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hepatic Veno- | 2016 |
Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation.
Topics: Adolescent; Area Under Curve; Busulfan; Child; Child, Preschool; Dose-Response Relationship, Drug; D | 2010 |
Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Busulf | 2010 |
Phase II study of dose-modified busulfan by real-time targeting in allogeneic hematopoietic stem cell transplantation for myeloid malignancy.
Topics: Adolescent; Adult; Busulfan; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Hemato | 2012 |
Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mo
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophospham | 2002 |
A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning.
Topics: Adult; Age Factors; Busulfan; Child; Cyclophosphamide; Drug Administration Schedule; Drug Carriers; | 2002 |
Busulfan induces activin A expression in vitro and in vivo: a possible link to venous occlusive disease.
Topics: Activin Receptors; Activins; Antineoplastic Agents, Alkylating; Area Under Curve; Busulfan; Cell Lin | 2003 |
In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa).
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2003 |
Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation.
Topics: Adolescent; beta-Thalassemia; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclop | 2004 |
Absence of veno-occlussive disease in a cohort of multiple myeloma patients undergoing autologous stem cell transplantation with targeted busulfan dosage.
Topics: Adult; Aged; Busulfan; Cause of Death; Cohort Studies; Drug Monitoring; Female; Hematopoietic Stem C | 2006 |
Elevated plasma ferritin and busulfan pharmacodynamics during high-dose chemotherapy regimens in children with malignant solid tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cyclo | 2007 |
Randomized comparison of four-times-daily versus once-daily intravenous busulfan in conditioning therapy for hematopoietic cell transplantation.
Topics: Adolescent; Adult; Busulfan; Drug Administration Schedule; Female; Graft Survival; Graft vs Host Dis | 2007 |
Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
Topics: Adult; Aged; Busulfan; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplanta | 2007 |
Safe administration of oral BU twice daily during conditioning for stem cell transplantation in a paediatric population: a comparative study between the standard 4-dose and a 2-dose regimen.
Topics: Administration, Oral; Busulfan; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; G | 2008 |
A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Cause of Death; Child; Child, Preschool; C | 1994 |
Etoposide with/without G-CSF with busulfan and cyclophosphamide as conditioning for bone marrow transplantation. The BMT Team.
Topics: Adolescent; Adult; Bone Marrow; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Drug Admini | 1996 |
Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial.
Topics: Adult; Bone Marrow Transplantation; Busulfan; Cholagogues and Choleretics; Cyclophosphamide; Double- | 1998 |
Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplanta
Topics: Adolescent; Adult; Alopecia; Bone Marrow Transplantation; Bronchiolitis Obliterans; Busulfan; Catara | 1999 |
Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia.
Topics: Adult; Antineoplastic Agents, Alkylating; Blast Crisis; Bone Marrow Transplantation; Busulfan; Cyclo | 1999 |
Pharmacokinetics of oral busulphan in children with beta thalassaemia major undergoing allogeneic bone marrow transplantation.
Topics: Administration, Oral; Adolescent; beta-Thalassemia; Bone Marrow Transplantation; Busulfan; Child; Ch | 1999 |
Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Cyclo | 1999 |
Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide.
Topics: Actuarial Analysis; Adult; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Female; Follow-U | 1992 |
97 other studies available for busulfan and Hepatic Veno Occlusive Disease
| Article | Year |
|---|---|
Association Between the Magnitude of Intravenous Busulfan Exposure and Development of Hepatic Veno-Occlusive Disease in Children and Young Adults Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation.
Topics: Administration, Intravenous; Busulfan; Child; Hematopoietic Stem Cell Transplantation; Hepatic Veno- | 2022 |
Prediction and recommendation by machine learning through repetitive internal validation for hepatic veno-occlusive disease/sinusoidal obstruction syndrome and early death after allogeneic hematopoietic cell transplantation.
Topics: Busulfan; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Machine L | 2022 |
Busulfan-induced hepatic sinusoidal endothelial cell injury: Modulatory role of pirfenidone for therapeutic purposes.
Topics: Busulfan; Chemical and Drug Induced Liver Injury; Endothelial Cells; Hepatic Veno-Occlusive Disease; | 2023 |
Secondary hemophagocytic syndrome after autologous hematopoietic cell transplant and immune therapy for neuroblastoma.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chil | 2019 |
Reduced Risk of Sinusoidal Obstruction Syndrome of the Liver after Busulfan-Cyclophosphamide Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation.
Topics: Acetylcysteine; Adolescent; Adult; Busulfan; Capillaries; Child; Child, Preschool; Cholagogues and C | 2020 |
Genetic Susceptibility to Hepatic Sinusoidal Obstruction Syndrome in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation.
Topics: Busulfan; Child; Genetic Predisposition to Disease; Glucuronosyltransferase; Hematopoietic Stem Cell | 2020 |
Busulfan clearance does not predict the development of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Biomarkers; Busulfan; Child; Female; Hematologic Neoplasms; Hematopoietic Stem Ce | 2020 |
Targeted-dose of busulfan: Higher risk of sinusoidal obstructive syndrome observed with systemic exposure dose above 5000 µMol⸱min. A historically controlled clinical trial.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Area Under Curve; Busulfan; Child; Ch | 2020 |
Hepatic Sinusoidal-obstruction Syndrome and Busulfan-induced Lung Injury in a Post-autologous Stem Cell Transplant Recipient.
Topics: Antineoplastic Agents, Alkylating; Busulfan; Child, Preschool; Fatal Outcome; Hematopoietic Stem Cel | 2017 |
Sinusoidal obstruction syndrome/veno-occlusive disease after high-dose intravenous busulfan/melphalan conditioning therapy in high-risk Ewing Sarcoma.
Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantatio | 2018 |
[A clinical analysis of hepatic veno-occlusive disease after hematopoietic stem cell transplantation].
Topics: Adolescent; Busulfan; China; Hematopoietic Stem Cell Transplantation; Heparin, Low-Molecular-Weight; | 2018 |
Maximal concentration of intravenous busulfan as a determinant of veno-occlusive disease: a pharmacokinetic-pharmacodynamic analysis in 293 hematopoietic stem cell transplanted children.
Topics: Administration, Intravenous; Adolescent; Adult; Busulfan; Child; Child, Preschool; Female; Hematopoi | 2019 |
Veno-occlusive disease after high-dose busulfan-melphalan in neuroblastoma.
Topics: Busulfan; Child; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Me | 2020 |
Improved clinical outcomes of high risk β thalassemia major patients undergoing a HLA matched related allogeneic stem cell transplant with a treosulfan based conditioning regimen and peripheral blood stem cell grafts.
Topics: Adolescent; beta-Thalassemia; Bone Marrow Cells; Busulfan; Cause of Death; Child; Child, Preschool; | 2013 |
Coexisting or underlying risk factors of hepatic veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients receiving prophylaxis.
Topics: Administration, Oral; Adolescent; Age Factors; Amphotericin B; Anticoagulants; Antifungal Agents; Bu | 2013 |
Evaluation of effects of busulfan and DMA on SOS in pediatric stem cell recipients.
Topics: Acetamides; Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemothera | 2014 |
Allogeneic hematopoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Busulfan; Databases, Factual; Disease-Free Sur | 2014 |
MTHFR C677T/A1298C genotype: a possible risk factor for liver sinusoidal obstruction syndrome.
Topics: Busulfan; Genetic Predisposition to Disease; Genotype; Hepatic Veno-Occlusive Disease; Humans; Methy | 2014 |
Evaluation of the effects of preconditioning regimens on hepatic veno-occlusive disease in mice after hematopoietic stem cell transplantation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blood Platelets; Busulfan; Cell | 2015 |
Economic and clinical aspects of intravenous versus oral busulfan in adult patients for conditioning prior to HSCT.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Busulfan; Drug Costs; Female; German | 2015 |
High pre-transplant serum ferritin and busulfan-thiotepa conditioning regimen as risk factors for hepatic sinusoidal obstructive syndrome after autologous stem cell transplantation in patients with malignant lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Ferritins | 2016 |
Subacute hepatic necrosis mimicking veno-occlusive disease in a patient with HFE H63D homozygosity after allogeneic hematopoietic cell transplantation with busulfan conditioning.
Topics: Acute Disease; Adult; Allografts; Busulfan; Diagnosis, Differential; Hematopoietic Stem Cell Transpl | 2015 |
Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool | 2016 |
Toxicities of busulfan/melphalan versus carboplatin/etoposide/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Child; Child, Pre | 2016 |
Levetiracetam for the prevention of busulfan-induced seizures in pediatric hematopoietic cell transplantation recipients.
Topics: Adolescent; Anticonvulsants; Busulfan; Child; Child, Preschool; Female; Graft Rejection; Hematopoiet | 2017 |
Diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome of the liver: problems of interpretation.
Topics: Bilirubin; Biopsy; Busulfan; Cyclophosphamide; Diagnosis, Differential; Hematology; Hepatic Veno-Occ | 2016 |
Association of CTH variant with sinusoidal obstruction syndrome in children receiving intravenous busulfan and cyclophosphamide before hematopoietic stem cell transplantation.
Topics: Administration, Intravenous; Adolescent; Adult; Busulfan; Child; Child, Preschool; Cyclophosphamide; | 2018 |
Mortality outcomes after busulfan-containing conditioning treatment and haemopoietic cell transplantation in patients with Gilbert's syndrome: a retrospective cohort study.
Topics: Adult; Bilirubin; Busulfan; Cohort Studies; Cyclophosphamide; Dose-Response Relationship, Drug; Fema | 2016 |
Risk factors for hepatic veno-occlusive disease: a retrospective unicentric study in 116 children autografted after a high-dose BU-thiotepa regimen.
Topics: Adolescent; Antineoplastic Agents; Brain Neoplasms; Busulfan; Carboplatin; Child; Child, Preschool; | 2008 |
Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; DNA; Female | 2008 |
The use of pharmacokinetic models in paediatric onco-haematology: effects on clinical outcome through the examples of busulfan and cyclosporine.
Topics: Bayes Theorem; Busulfan; Child; Computer Simulation; Cyclosporine; Drug Administration Schedule; Dru | 2008 |
Absence of VOD in paediatric thalassaemic HSCT recipients using defibrotide prophylaxis and intravenous Busulphan.
Topics: Adolescent; beta-Thalassemia; Busulfan; Child; Child, Preschool; Drug Evaluation; Female; Graft vs H | 2009 |
Excessive toxicity of once daily i.v. BU, melphalan and thiotepa followed by auto SCT on patients with non-Hodgkin's lymphoma.
Topics: Adult; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Hu | 2010 |
Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Busulfan; Combined | 2009 |
[Usefulness of serum plasminogen activator inhibitor-1 for diagnosis and monitoring of late-onset sinusoidal obstruction syndrome after allogeneic stem cell transplantation].
Topics: Adolescent; Biomarkers; Busulfan; Diagnosis, Differential; Follow-Up Studies; Hepatic Veno-Occlusive | 2010 |
Order of application and liver toxicity in patients given BU and CY containing conditioning regimens for allogeneic hematopoietic SCT.
Topics: Adolescent; Adult; Aged; Busulfan; Chemical and Drug Induced Liver Injury; Cohort Studies; Cyclophos | 2011 |
Weight-based strategy of dose administration in children using intravenous busulfan: clinical and pharmacokinetic results.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Area Under Curve; Body Weight; Busulfan; Child; Child | 2012 |
[Effects of pretreatment regimen on mice liver injury in hematopoietic stem cell transplantation].
Topics: Animals; Busulfan; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Hepatic Veno-O | 2010 |
Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Area Under Curve; Biopsy; Busulfan; Dose-Resp | 2012 |
Antineoplastic agent busulfan regulates a network of genes related to coagulation and fibrinolysis.
Topics: Activins; Antineoplastic Agents, Alkylating; Benzamides; Blood Coagulation; Busulfan; Cell Line, Tum | 2012 |
Prognostic value of doppler-ultrasonography in hepatic veno-occlusive disease.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bilirubin; Brain Neoplasms; Busulfan; Child; C | 2002 |
Prognostic value of doppler-ultrasonography in hepatic veno-occlusive disease.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bilirubin; Brain Neoplasms; Busulfan; Child; C | 2002 |
Prognostic value of doppler-ultrasonography in hepatic veno-occlusive disease.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bilirubin; Brain Neoplasms; Busulfan; Child; C | 2002 |
Prognostic value of doppler-ultrasonography in hepatic veno-occlusive disease.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bilirubin; Brain Neoplasms; Busulfan; Child; C | 2002 |
Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulphan and cyclophosphamide.
Topics: Adolescent; Adult; Autoantigens; Bilirubin; Biomarkers; Body Weight; Bone Marrow Transplantation; Bu | 2002 |
Parenteral busulfan: is therapeutic monitoring still warranted?
Topics: Bone Marrow Transplantation; Busulfan; Drug Monitoring; Hepatic Veno-Occlusive Disease; Humans; Infu | 2002 |
Re: intravenous versus oral busulfan--perhaps not as different as suggested.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Area Under Curve; Busulfan; Hematologic Neo | 2003 |
Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results.
Topics: Area Under Curve; Busulfan; Chromatography, High Pressure Liquid; Drug Evaluation; Drug Monitoring; | 2003 |
Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity.
Topics: Adolescent; Area Under Curve; Busulfan; Child; Child, Preschool; Drug-Related Side Effects and Adver | 2005 |
Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation.
Topics: Administration, Oral; Adult; Blood Proteins; Bone Marrow Transplantation; Busulfan; Case-Control Stu | 2005 |
Platelet transfusion containing ABO-incompatible plasma and hepatic veno-occlusive disease after hematopoietic transplantation in young children.
Topics: ABO Blood-Group System; Adolescent; Antineoplastic Agents; Brain Neoplasms; Busulfan; Chemical and D | 2005 |
Once-daily intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics and early clinical outcomes.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Area Under Curve; Busulfan; Child; Child, Preschool; | 2006 |
Induction of glutathione synthesis explains pharmacodynamics of high-dose busulfan in mice and highlights putative mechanisms of drug interaction.
Topics: Animals; Bone Marrow Transplantation; Busulfan; Drug Interactions; Glutathione; Glutathione Transfer | 2007 |
Hepatic injury following reduced intensity unrelated cord blood transplantation for adult patients with hematological diseases.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Busulfan; Chemical and Drug In | 2006 |
Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Busulfan; Cause of Death; Cohort Studies; Cyclophosphamide; Disease-Free Su | 2006 |
Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation.
Topics: Area Under Curve; Busulfan; Child; Child, Preschool; Drug Evaluation; Female; Graft Survival; Hemato | 2007 |
[Low dose heparin for the prevention of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation].
Topics: Adult; Busulfan; Child; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Heparin; | 2007 |
Busulphan-loaded long-circulating nanospheres, a very attractive challenge for both galenists and pharmacologists.
Topics: Antineoplastic Agents, Alkylating; Busulfan; Calorimetry, Differential Scanning; Delayed-Action Prep | 2007 |
Risk-adjusted monitoring of veno-occlusive disease following Bayesian individualization of busulfan dosage for bone marrow transplantation in paediatrics.
Topics: Adolescent; Bayes Theorem; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cytomegal | 2008 |
Defibrotide in the prevention and treatment of veno-occlusive disease in autologous and allogeneic stem cell transplantation in children.
Topics: Adolescent; Busulfan; Child; Child, Preschool; Female; Fibrinolytic Agents; Graft vs Host Disease; H | 2008 |
Functional hyperactivity of monocytes after bone marrow transplantation: possible relevance for the development of post-transplant complications or relapse.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopterins; Bone Marr | 1995 |
Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia.
Topics: Actuarial Analysis; Adolescent; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cycl | 1995 |
The syndrome of hepatic veno-occlusive disease after marrow transplantation.
Topics: Alprostadil; Biopsy; Bone Marrow Transplantation; Busulfan; Clinical Trials as Topic; Combined Modal | 1995 |
Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted?
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Drug Monitoring; Eating; Female; He | 1994 |
Toxicity of high-dose busulphan and cyclophosphamide as conditioning therapy for allogeneic bone marrow transplantation in adults with haematological malignancies.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cyclop | 1994 |
Intravenous pentoxifylline failed to prevent transplant-related toxicities in allogeneic bone marrow transplant recipients.
Topics: Adolescent; Adult; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Child; Cyclophosphami | 1993 |
Chronopharmacology of high-dose busulfan in children.
Topics: Bone Marrow Transplantation; Brain Neoplasms; Busulfan; Child; Child, Preschool; Circadian Rhythm; D | 1993 |
Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone | 1996 |
Association of busulfan area under the curve with veno-occlusive disease following BMT.
Topics: Adolescent; Adult; Aged; Bone Marrow Transplantation; Busulfan; Circadian Rhythm; Cyclophosphamide; | 1996 |
Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only condition regimen. Low incidence of failed engraftment and severe acute GVHD.
Topics: Actuarial Analysis; Acute Disease; Adult; Anti-Infective Agents; Bone Marrow Transplantation; Busulf | 1996 |
Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bone Marrow Transplantation; Busulfan; Child; Child, | 1996 |
Hepatic veno-occlusive disease after myeloablative treatment and bone marrow transplantation: value of gray-scale and Doppler US in 100 patients.
Topics: Adult; Busulfan; Child; Diagnosis, Differential; Female; Graft vs Host Disease; Hematopoietic Stem C | 1997 |
Hepatic veno-occlusive disease after myeloablative treatment and bone marrow transplantation: value of gray-scale and Doppler US in 100 patients.
Topics: Adult; Busulfan; Child; Diagnosis, Differential; Female; Graft vs Host Disease; Hematopoietic Stem C | 1997 |
Hepatic veno-occlusive disease after myeloablative treatment and bone marrow transplantation: value of gray-scale and Doppler US in 100 patients.
Topics: Adult; Busulfan; Child; Diagnosis, Differential; Female; Graft vs Host Disease; Hematopoietic Stem C | 1997 |
Hepatic veno-occlusive disease after myeloablative treatment and bone marrow transplantation: value of gray-scale and Doppler US in 100 patients.
Topics: Adult; Busulfan; Child; Diagnosis, Differential; Female; Graft vs Host Disease; Hematopoietic Stem C | 1997 |
High-dose busulphan/melphalan with autologous stem cell rescue in Ewing's sarcoma.
Topics: Adolescent; Adult; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; | 1997 |
Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation.
Topics: Adolescent; Adult; Anticoagulants; Antithrombin III; Bone Marrow Transplantation; Busulfan; Child; C | 1997 |
[Severe hepatic veno-occlusive disease (VOD) which was successfully treated with supportive therapy, but subsequently developed late-recurrence].
Topics: Adult; Bone Marrow Transplantation; Busulfan; Chronic Disease; Cyclophosphamide; Cyclosporine; Graft | 1998 |
Color-flow imaging sonography of portal and hepatic vein flow to monitor fibrinolytic therapy with r-TPA for veno-occlusive disease following myeloablative treatment.
Topics: Acute Disease; Adolescent; Busulfan; Combined Modality Therapy; Cyclophosphamide; Fibrinolytic Agent | 1998 |
Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation.
Topics: Administration, Oral; Adult; Animals; Biological Availability; Busulfan; Dimethyl Sulfoxide; Dogs; H | 1998 |
Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; | 2000 |
Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemoth | 2000 |
The influence of early transplantation, age, GVHD prevention regimen, and other factors on outcome of allogeneic transplantation for CML following BuCy.
Topics: Adolescent; Adult; Age Factors; Aged; Bone Marrow Transplantation; Busulfan; Cause of Death; Cycloph | 2000 |
Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2001 |
A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Topics: Adult; Anemia, Refractory, with Excess of Blasts; Antilymphocyte Serum; Bone Marrow; Busulfan; Cell | 2001 |
Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.
Topics: Adolescent; Alkylating Agents; Area Under Curve; Bayes Theorem; Bone Marrow Transplantation; Busulfa | 2001 |
Toxicity of high-dose busulfan and cyclophosphamide as a preparative regimen for bone marrow transplantation.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cystitis; Dose-Response | 1992 |
Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children.
Topics: Adolescent; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Female; Hepatic Veno-Occ | 1992 |
A canine model for hepatic venoocclusive disease.
Topics: Animals; Bone Marrow Transplantation; Busulfan; Disease Models, Animal; Dogs; Hepatic Veno-Occlusive | 1992 |
High-dose chemotherapy containing busulfan followed by bone marrow transplantation in 24 children with refractory or relapsed non-Hodgkin's lymphoma.
Topics: Adolescent; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Dose-Res | 1991 |
Improved results of allogeneic bone marrow transplantation for advanced hematologic malignancy using busulfan, cyclophosphamide and etoposide as cytoreductive and immunosuppressive therapy.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Combined Modality Therapy; Cyclopho | 1991 |
Haemostatic changes in uncomplicated bone marrow transplants.
Topics: Biomarkers; Blood Coagulation Factors; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Endo | 1991 |
Hepatic veno-occlusive disease post-bone marrow transplantation in children conditioned with busulfan and cyclophosphamide: incidence, risk factors, and clinical outcome.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; | 1991 |
The toxicity of busulphan and cyclophosphamide as the preparative regimen for bone marrow transplantation.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cystitis; Drug Therapy, | 1991 |
[Hepatic veno-occlusive disease in a patient undergoing bone marrow autotransplant after busulfan and melphalan conditioning].
Topics: Adult; Bone Marrow Transplantation; Busulfan; Female; Hepatic Veno-Occlusive Disease; Humans; Melpha | 1990 |
Busulfan and veno-occlusive disease of the liver.
Topics: Bone Marrow Transplantation; Busulfan; Child; Dose-Response Relationship, Drug; Hepatic Veno-Occlusi | 1990 |
Frequency of veno-occlusive disease of the liver in bone marrow transplantation with a modified busulfan/cyclophosphamide preparative regimen.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu | 1990 |
Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation.
Topics: Absorption; Bone Marrow Transplantation; Busulfan; Chromatography, High Pressure Liquid; Cyclophosph | 1989 |
Nodular regenerative hyperplasia of the liver following bone marrow transplantation.
Topics: Bone Marrow Transplantation; Busulfan; Hepatic Veno-Occlusive Disease; Humans; Hyperplasia; Liver; L | 1989 |
[Liver damage during use of busulfan].
Topics: Busulfan; Chemical and Drug Induced Liver Injury; Diagnosis, Differential; Hepatic Veno-Occlusive Di | 1989 |
Induction of hepatic veno-occlusive disease in dogs.
Topics: Animals; Busulfan; Buthionine Sulfoximine; Cyclophosphamide; Disease Models, Animal; Dog Diseases; D | 1987 |
Allogeneic and syngeneic marrow transplantation following high dose dimethylbusulfan, cyclophosphamide and total body irradiation.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; | 1987 |
Preparative regimens for marrow transplantation containing busulphan are associated with haemorrhagic cystitis and hepatic veno-occlusive disease but a short duration of leucopenia and little oro-pharyngeal mucositis.
Topics: Anemia, Aplastic; Bone Marrow Transplantation; Busulfan; Cystitis; Hemorrhage; Hepatic Veno-Occlusiv | 1987 |